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Abstract
Detection of circulating tumor cells has emerged as a promising minimally invasive diagnostic and
prognostic tool for patients with metastatic cancers. We report a novel three dimensional
microfilter device that can enrich viable circulating tumor cells from blood. This device consists of
two layers of parylene membrane with pores and gap precisely defined with photolithography. The
positions of the pores are shifted between the top and bottom membranes. The bottom membrane
supports captured cells and minimize the stress concentration on cell membrane and sustain cell
viability during filtration. Viable cell capture on device was investigated with scanning electron
microscopy, confocal microscopy, and immunofluorescent staining using model systems of
cultured tumor cells spiked in blood or saline. The paper presents and validates this new 3D
microfiltration concept for circulation tumor cell enrichment application. The device provides a
highly valuable tool for assessing and characterizing viable enriched circulating tumor cells in
both research and clinical settings.
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1 Introduction
According to the American Cancer Society, cancer is projected to be the leading cause of
death worldwide in 2010 (Boyle and Levin 2008). Malignancies derived from the
epithelium, carcinoma, constitute the majority of the cancer incidence and over 90% of
death among carcinoma patients are caused by metastatic tumors (Crnic and Christofori
2004). Metastasis is the spread of cancer from the primary site to non-adjacent secondary
sites through a series of sequential steps. According to the current model, the “invasion-
metastasis cascade” includes localized invasion, intravasation, transport through circulation,
arrest in microvessels, extravasation, formation of a micrometastasis and dormancy, and
finally angiogenesis, colonization and formation of a macrometastsis (Pantel and Brakenhoff
2004; Gupta and Massague 2006; Steeg 2006; Sahai 2007; Weinberg 2007). While the
tumor cells are transported in the circulatory system, they are referred as circulating tumor
cells (CTC) in bloodstream and disseminated tumor cells (DTC) in bone marrow (Braun and
Naume 2005; Smerage and Hayes 2006; Alix-Panabieres et al. 2008; Pantel et al. 2008).
CTCs are prognostically critical, associated with clinical stage, disease recurrence, tumor
metastasis, treatment response, and patient survival following therapy (Cristofanilli et al.
2004; Cristofanilli et al. 2005; Budd et al. 2006; Hayes et al. 2006). There is a growing body
of literature demonstrating CTC to be an emerging surrogate and independent marker for
assessing the risk of relapse, guiding course of therapy and treatment monitoring (Hanahan
and Weinberg 2000; Dirix et al. 2005; Cristofanilli and Mendelsohn 2006; Gupta and
Massague 2006; Meng et al. 2006; Dawood et al. 2008; Hayes and Smerage 2008).
The main technical challenge of CTC detection arises due to its rarity, at the level of 1 CTC
in 7.5 mL of blood (or 1 CTC against 1010 blood cells), making efficient enrichment a
prerequisite for CTC detection in most of the cases. Various CTC enrichment methods
exploit the intrinsic differences between the epithelial derived CTCs (Weinberg 2007) and
hematogeneous blood cells. Traditionally, density gradient centrifugation is employed to
enrich the mononucleocyte (MNCs) fraction, which includes CTCs due to their similar
buoyant density (Cote et al. 1991; Baker et al. 2003; Lara et al. 2004; Pantel and Brakenhoff
2004). Interpreting the immunofluorescent staining results requires a trained pathologist to
examine each slide for the presence of CTCs, which is both time consuming and subjective.
Moreover, density gradient centrifugation has a maximum recovery rate of ~70%. More
recent technologies take advantages of specific epithelial surface antigens such as epithelial
cell adhesion molecule (EpCAM) for selective capture of CTCs. Cellsearch™ is the only
FDA approved automated system to capture and assess CTCs for prognosis and treatment
monitoring in metastatic breast, colorectal or prostate cancer. It is based on
immunomagnetic separation (Hardingham et al. 1993; Racila et al. 1998; Benez et al. 1999;
Allard et al. 2004; Lara et al. 2004; Riethdorf et al. 2007), in which EpCAM conjugated
magnetic beads are used to capture EpCAM positive CTCs from blood under magnetic field.
Although plenty of clinical studies substantiate its prognostic value, the assay is expensive,
labor intensive and subject to a large range of recovery rates (9%–90%) (Lara et al. 2004)
mainly due to variable expression of surface markers. Recently an immunoaffinity based
“CTC chip”, where CTCs are captured with antibodies conjugated to surface of micro posts
in a microflow chamber, has successfully demonstrated CTC capture and detection from
patient samples of multiple metastatic cancers (Nagrath et al. 2007; Maheswaran et al.
2008). While viable CTCs with high purity can be obtained, the capture efficiency is limited
by the variability of surface antigen expression and the throughput and processing time is
limited by allowable maximal flow rate.
Alternatively, isolation of CTC based on cell size has been demonstrated to be a potentially
efficient, inexpensive and quick way for CTC enrichment (Vona et al. 2000; Vona et al.
2002; Kahn et al. 2004; Vona et al. 2004; Pinzani et al. 2006), dating back to 1960s (Seal
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1964; Fleischer et al. 1965). Circulating tumor cells are in most of the cases epithelial cells
and believed to be significantly larger than the surrounding blood cells (Vona et al. 2000;
Lara et al. 2004; Lin et al. 2008). Pore size around 8 μm in diameter has been shown to be
optimal for CTC retention (Zabaglo et al. 2003). However, the previously described
polycarbonate filters are fabricated using track etching (Fleischer et al. 1972), which can
only generate pores at random locations. Low pore density and multiple pore fusion lead to
low CTC capture efficiency (~50–60%) and frequent sample clogging on filter (Rostagno et
al. 1997; Lara et al. 2004). Recently microfabricated filters have shown better promise for
size based CTC enrichment. We have previously reported the utility of microfabricated
single layer (2D) microfilter devices for CTC enrichment (Zheng et al. 2007; Lin et al.
2010). Filters with high density uniform circular pores were made using photolithography
processes in a cost-effective way. The device has superior performance in CTC enrichment
with clinical samples from metastatic cancer patients. In another study, traps in a
microfluidic flow chamber capture tumor cells from blood under low shear stress with high
purity and viability (Tan et al. 2009). More recently a microcavity array device made by
nickel electroforming have demonstrated trapping and detection of tumor cells from blood
with high capture efficiency and viability (Hosokawa et al. 2010).
Our previous version of the 2D pore microfilter device is suitable for CTC enumeration in
blood from metastatic cancer patients with high recovery and short processing time;
however, samples are required to be partially fixed, incompatible for further live cell
interrogations. The ability to capture viable and proliferative CTC may pave the way for
functional studies, such as the recently proposed cancer stem cells giving rise to relapse in
cancer patients (Reya et al. 2001; Wicha et al. 2006; Stingl and Caldas 2007). The object of
the current study is to capture viable tumor cells by controlling the micro environment of the
trapped cells with a novel 3D device structure design.
2 Experimental
2.1 Device design
Cell membrane damage has been associated with mechanical trauma, which can be induced
by passage through filter pores (Gabor and Weiss 1985; Weiss and Schmidschonbein 1989).
Micropipette experiments on artificial phospholipids show membrane rupture happens when
membrane tension increases above a critical level, i.e. membrane area increment exceeding
3% (Evans et al. 1979). The tension at which cell lysis occurs may be as low as 3 mN/m in
these membrane models (Kwok and Evans 1981). The maximum tensions at the surfaces of
seven different types of cancer cells, measured from micropipet-deformability study, have a
median value of 3.7 mN/m and range from 0.8 to 5.0 mN/m (Weiss and Schmidschonbein
1989). We think for a particular tumor cell, the damage can result from either of the two
stages of the filtration process. The first stage starts from when the cell begins to have
interaction with the pore edge until this is fully trapped. This is a dynamic process which
happens within millisecond range in our experimental conditions. The second stage is from
this fully entrapment to the end of the overall filtration process. During this stage, the cell
will experience the static pressure. Under 3.45×103 Pa (0.5 psi) constant pressure we used in
a previous study (2D microfilters of 8 μm diameter pore size), cytoplasm membrane tension
is estimated by finite element simulation to be 13.8 mN/m at the contact circumference to
the device. Compared with the critical tension for cell rupture, even this tension due to the
2nd stage static pressure can cause cell damage.
The concentrated tension stress exerted by the device edges is the primary cause for cell
damage. To reduce it, the new 3D microfilter has two layers of membranes. Both the top and
bottom layers have pores defined by micro-fabrication. The gap between the two layers is
defined precisely by photolithography. An important feature of the device is that the pore
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positions of the bottom membrane are shifted from the pore positions of the top membrane.
So if tumor cells are trapped in the pores of the top membrane, the bottom membrane can
provide direct force in the opposite direction and effectively reduce the concentrated tension
stress on cell plasma membrane (Fig. 1(a)). The tension reduction applies to both the
dynamic process during which the cell is plugged into a pore, and later when the cell is
under static pressure. As shown in Fig. 1(b), each microfilter patch has thirty-six 9 μm
diameter pores on the top membrane and thirty-seven 8 μm diameter pores on the bottom
membrane. Also the gap formed by the top and bottom membrane allows smaller flow-
through cells to traverse through while blocking large cells, which effectively acts as a third
critical dimension during filtration.
2.2 Device fabrication
To fabricate the device, first alignment marks were generated on both sides of a prime
silicon wafer followed by 1 μm-thick thermal oxidation, backside oxide patterning and
front-side oxide stripping as shown in Fig. 2. A 5 μm-thick parylene-C (poly(monochloro-p-
xylylene), referred as parylene below) thin film was deposited on the front-side and melted
at 350°C, forming a molten parylene layer that eventually integrates as part of the bottom
filter and also provides front side protection during wet etching. Next on each of the 1×1
cm2 die, nine through-wafer cavities were etched by tetramethylammonium hydroxide
(TMAH) from backside, with silicon dioxide as etching mask. A 2.5 μm-thick second
parylene layer was deposited from both sides and patterned with oxygen plasma. In the
cavity regions, the molten parylene layer was sandwiched between this second parylene
layer to form the bottom filter layer. Then 6.5 μm-thick sacrificial photoresist AZ4620 was
spin-coated and patterned, followed by 10 μm-thick parylene deposition and patterning from
front-side, forming the top filter layer of the 3D microfilter. Finally, sacrificial photoresist
was dissolved in acetone followed by a 190°C parylene annealing step to strengthen the
overall structure. The pore size, shape and density in this 3D microfilter were defined by
photolithography, while the gap between the top and bottom membranes was defined by the
thickness of the sacrificial photoresist.
As shown in Fig. 3, a fabricated 3D microfilter is a 1× 1 cm2 device with two layers of
parylene on a silicon substrate. The device has nine open windows of effective filtration
area. The open windows are formed by wet etching of silicon substrate for form cavities. In
order to maintain the gap distance during filtration, each cavity are arranged into 99
hexagonal microfilter patches as Fig. 1(b), where the top and bottom parylene membrane
layers are in contact and annealed along the patch edges to provide structural support.
2.3 Device assembly
To introduce samples to the 3D microfilter, it is assembled into a custom made housing
cassette. The microfilter is clamped between four pieces of polydimethylsiloxane (PDMS)
and two machined acrylic parts (Fig. 4). The two thin PDMS pieces (~1 mm thick) have an
8×8 mm2 central square hole, which forms a chamber for sample to flow through the 3D
filtration device. One of the two thick PDMS pieces (~4 mm thick) has a small circular
central hole as a receiving port for sample injection directly from a syringe. The other thick
PDMS piece has a large square hole open to atmosphere pressure for filtrate collection. The
two acrylic pieces have a central hole of 3 mm diameter. The samples were manually pushed
through the experimental assembly.
2.4 Fluidic simulation of microfilter devices
Due to the complexity of the dynamic process of cell trapping, here we only studied the
effects of static back pressure induced cell membrane tension during the filtration process.
We compare the 2D microfilters with the 3D microfilters. For 2D microfilter devices, we
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simulated a membrane piece of 25 pores in a five by five array with 30 μm distance among
the pores. For 3D microfilter devices, we simulated a single patch as shown in Fig. 1 (b).
The modeling and simulations of the fluidic field were performed by using incompressible
Navier-Stokes steady-state analysis with Comsol Multiphysics. According to the properties
of human blood, the fluid density is chosen as 1025 kg/m3, and the dynamic viscosity is
3×10−3 Pa·s without considering the partial fixation required for the current protocol using
the 2D microfilters. For the real devices, blood flows into the chamber between the top
PDMS sheets and top parylene layer before it reaches the filter, so as is in the models. “Slip/
symmetry” boundary conditions were used on the side walls to represent the repeated
structure. No-slip boundary conditions were used for elsewhere except for inflow and
outflow surface. Assuming the same equivalent total area on the 1×1 cm2 device and the
same processing time of the 2D and 3D devices (7.5 mL of blood filtered in 2 min), an
inflow rate of 0.002 m/s was applied on the top surface for both cases. A zero pressure
condition was applied to outflow surface.
As shown in Fig. 5(a), the simulated fluid field is almost uniformly distributed on the 3D
microfilter device, although the positions of the pores are shifted and the top pores
themselves are not symmetrically located. Therefore, the simulation results verify that all the
pores on the same patch can be efficiently used in the same way without significant edge
effect.
We also simulated cases where an increasing number of cells are plugged in the pores
surrounding a central open pore (Fig. 5(b)). For simplicity, we made the filter membrane
continuous at the plugged pore position without using any cell geometry. Pressure was
measured locally at the surrounding plugged pores to estimate the tension on a trapped cell,
and at the central open pore to estimate the tension on an unblocked pore. For comparison
with the critical membrane tension, the pressure differences are converted to tension
according to , where r is the radius of the pore. The tension on a trapped cell is an
estimation of the tension of cell membrane at the pore edge after it plugs under the applied
static back pressure. For 3D microfilter case, we did not consider the supporting force on a
trapped cell from the bottom membrane and instead just using the local pressure on the
surface of the bottom membrane. The real membrane tension for the 3D cases should be
even smaller. As shown in the simulation, this overestimated tension on cell for the 3D
devices is only about 50% or smaller compared with that of the 2D devices. The tension on a
trapped cell for 2D devices is in the range of the critical membrane tension of tumor cells
mentioned earlier, which suggests even the static pressure can damage the cells due to
plasma membrane rupture. Tension on unblocked pore is calculated from the local pressure
for an open pore with some of its neighboring pores being blocked. Higher local pressure on
unblocked pore is likely to cause larger cell membrane tension during the dynamic process
of cell plugging into the pore, thus causing cell damage. The local pressure on unblocked
pore of 2D devices is about 3 times larger than that of the 3D devices, which suggests cells
are more likely to be damaged during the dynamic trapping process in 2D devices compared
with the 3D devices.
2.5 SEM sample preparation
Sodium cacodylate, glutaraldehyde, and osmium tetroxide were all purchased from
Polysciences, Warrington, PA, USA. After sample filtration, the device was first rinsed in
Dulbecco’s phosphate buffered saline (PBS) for two minutes and replaced with primary
glutaraldehyde fixative (0.1 M sodium cacodylate, 5% glutaraldehyde, 0.1 M sucrose, pH
7.4 in PBS) in fume hood for 45 min with occasionally gentle mixing. The glutaraldehyde
fixative was later removed and replaced with buffered sucrose vehicle (0.1 M sodium
cacodylate, 0.1 M sucrose, pH 7.4) for 30 min followed by incubation with secondary
Zheng et al. Page 5
Biomed Microdevices. Author manuscript; available in PMC 2013 October 28.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
osmium fixative (0.1 M sodium cacodylate, 0.1 M sucrose, 1% osmium tetroxide, pH 7.4)
for 60 min. Dehydration and drying procedure started with 5 min distilled water wash twice,
followed by sequentially immersing the device in 35%, 70%, 85%, and 95% ethanol for 10
min each, and 100% ethanol for 20 min. Finally the device was inserted in 100%
hexamethyldisilazane (HMDS) for 5 min and kept in desiccator before observation with an
Oxford LEO 1550VP field emission scanning electron microscope (SEM).
2.6 Cell culture and live cell labeling
Human prostate adenocarcinoma cell line (LNCaP) and human breast adenocarcinoma cell
line (MCF-7) were purchased from American Type Culture Collection (Manassas, VA,
USA) and cultured using recommended media and conditions in a humidified incubator at
5% CO2 and 37°C. Adherent cells were harvested using GIBCO® Trypsin-EDTA
(Invitrogen, Carlsbad, CA, USA) and cell counts were assessed using hemocytomter.
Harvested cells were washed twice in PBS and resuspended to concentration of ~106 cells/
mL. Cells were labeled with carboxyfluorescein diacetate, succinimidyl ester (CFDA-SE,
Invitrogen, Carlsbad, CA, USA) by incubation with final concentration of 20 μM CFDA-SE
at 37°C for 15 min followed by 30 min incubation in complete medium at 37°C. Labeled
cells were washed twice in PBS before use.
2.7 Cell labeling for confocal microscopy
To better define the boundary of the cells trapped on device, CFDA-SE labeled cells were
further labeled with Lissamine™ Rhodamine B 1,2-dihexadecanoyl-sn-glycero-3-
phosphoethanolamine, triethylammonium (rhodamine DHPE, Invitrogen, Carlsbad, CA,
USA). The labeling procedure started with making a 1 mM stock solution of Rhodamine
DHPE in ethanol. CFDA-SE labeled cells were suspended in PBS at a concentration of 106
cells/mL. Rhodamine DHPE was added to the cell suspension with the final concentration of
1 μM. The mixture was then incubated for 5 min at 37°C. Finally cells were centrifuged,
rinsed once with PBS, resuspended in PBS and put in a live cell imaging chamber for
confocal microscopy study with a Zeiss LSM Pascal inverted laser scanning microscope.
Images were processed with Zeiss LSM software.
2.8 Immunofluorescent (IF) analysis
Samples were prepared by passing known quantities of cultured tumor cells (MCF-7 and
LNCaP) in PBS or blood from healthy donors through the 3D microfilter devices. Devices
with captured cells were first rinsed with PBS twice followed by fixation with 10% neutral
buffered formalin for 20 min. Fixed samples were washed with PBS and ready for IF
analysis mostly using antibodies obtained from Invitrogen, Carlsbad, CA unless noted
otherwise. A cocktail of two different mouse monoclonal antibodies against cytokeratins
(CKs) was used for the detection of epithelial tumor cells: AE-1 (1:600 dilution, Signet,
Dedham, MA, USA) against low and intermediate Type I acidic keratins and CAM 5.2
(1:100 dilution, Beckton-Dickinson, San Jose, CA, USA) against CK 8 and 18. The devices
were incubated for 1 h in the cocktail of primary antibodies diluted in CheMate antibody
diluent (DakoCyotmation, Carpinteria, CA, USA). Subsequently, the devices were washed
and incubated for 1 h with Alexa Fluor 488 conjugated goat anti-mouse secondary antibody.
To confirm captured CK positive cells were of prostate origin in LNCaP spiked samples, a
double staining was used. Rabbit anti-CK was used as the 1st primary antibody and Alexa
Fluor 568 conjugated goat anti-rabbit IgG as the 1st secondary antibody for detection of CK.
It was followed by IF staining using mouse anti-PSA as the 2nd primary antibody and Alexa
Fluor 488 conjugated goat anti-mouse IgG as the 2nd secondary antibody for detection of
prostate originated cells. The IF images were obtained using a Nikon Eclipse 80i microscope
(Nikon, Japan) with B-2E/C filter cube for green fluorescent channel and G-2E/C for red
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fluorescent channel and a cooled CCD camera (RT-KE color 3-shot, Diagnostic Instruments,
Sterling Heights, MI, USA) for image capture.
2.9 Cell viability assay on cellular metabolic level
CFDA-SE labeled cells mixed with blood from healthy donors were filtered through the
device, washed with PBS, and cultured in a petri dish for 2 weeks. On the 14th day, the
device was washed twice with PBS and C12-resazurin was added to the petri dish containing
the device at a final concentration of 5 μM. The reaction mixture was allowed to incubate
for 15 min in a humidified incubator at 5% CO2 and 37°C. Excess amount of PBS was
added to the petri with gentle mixing and analyzed under epi fluorescent microscope with
red emission filter block (Nikon G-2E/C) immediately.
3 Results and discussion
3.1 Cell capture efficiency
Since CTCs are rare occurrences in blood, it is important to retain maximum number of
target cells in a blood sample and we have characterized the capture efficiency of our 3D
device with a model system. The model system is constructed by spiking a known number
of CFSE labeled MCF-7 cells into blood obtained from healthy donors. 342±58 MCF-7 cells
were spiked in 1 mL of whole blood obtained from healthy donors and diluted with 9 mL of
PBS before passing through the 3D microfilter devices. During filtration, a constant pressure
of approximate 3.45×103 Pa (0.5 psi) is used to push samples through the device. It took
about 3–5 min to finish the filtration process. Numbers of captured cells were manually
counted under fluorescence microscope right after filtration (Table 1) with the average of
296±16 (n=4) captured cells and capture efficiency of 86.5±5.3%, which is comparable to
our previously reported data obtained using single layer 2D microfilter device (Zheng et al.
2007). The sample volume of the device is limited to about 1 mL of whole blood. Larger
volume results in clogging of the device. Assuming pores are eventually clogged by single
large leukocytes with normal count ranging from 4.5–11× 106/mL, the enrichment of the
device is on the order of 103, given total pore numbers about 7000 on a single device. This is
close to our previous 2D pore shaped microfilter device (Lin et al. 2010). If larger sample
volume is desired, either multiple devices or device of larger size (e.g. 3 cm by 3 cm instead
of 1 cm by 1 cm) can be used.
3.2 Comparison of 2D and 3D microfilter devices for cell capture
A sided by side comparison was performed between 2D and 3D microfilter devices by
filtering unfixed CFDA-SE labeled MCF-7 cells under the same flow rates. The 2D
microfilter device failed to retain intact cells as shown in Fig. 6(b) in comparison to a
positive control prepared by pipetting a droplet of buffer containing labeled cells on a 2D
microfilter device without filtration (Fig. 6(a)). Moreover, intact cells were not observed in
the filtrate of the sample, which rules out the possibility of intact cells squeezing through the
pores and suggests cell lysis during filtration. Under careful examination using fluorescence
microscope, faint green fluorescence can be observed on the 2D devices coming from the
edges of pores, which were thought to be cell membrane remnants and later confirmed by
SEM (Fig. 6(b) inset). On the contrary, 3D device can capture MCF-7 cells while preserving
cell membrane integrity as demonstrated by the bright green fluorescence indicating intact
cytoplasm as shown in Fig. 6(c). This direct comparison between the 2D and 3D microfilter
devices clearly demonstrates the capability of 3D device for capturing viable unfixed tumor
cells.
The pore density of the 2D devices is normally about 1.12×105/cm2, which corresponds to
porosity (open pore area to overall area) of 5.6%. While higher density 2D filters of
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2.5×105/cm2 (porosity 12.6%) was fabricated, the high pore density introduces local
membrane distortion during filtration and makes image observation difficult. With the
current 3D microfilter device, each patch has a pore density of about 2.89×105/cm2,
corresponding to a porosity of 14.5%; however, considering the border effect of each patch,
the pore density and porosity drops to 1.39× 105/cm2 and 6.96% respectively. Regardless,
the porosity of 2D and 3D microfilters is much higher than conventional track etched
polycarbonate filters, which has a reported fill factor of less than 2% to avoid significant
pore overlapping during fabrication (Fleischer et al. 1964). Higher pore density facilitates
filtration of larger sample volume without clogging. It also enables using smaller membrane,
which presents the captured cell in a smaller area for observation or scanning and make the
overall process more efficient.
3.3 SEM and confocal microscopy studies of tumor cells captured on 3D devices
To confirm the capture of intact unfixed cells on the 3D microfilter device, approximately
200 MCF-7 cells in 1 mL of PBS was filtered through a 3D microfilter device and observed
with SEM. As shown in Fig. 7(a), a cell with intact membrane was captured and sitting on a
pore of the top filter layer with the cell size comparable to expected diameter of 13.6±1.3
μm. Furthermore, fluorescence confocal microscopy was used to examine how the cells
were captured on the 3D microfilter. The cytoplasm of MCF-7 cells was labeled with green
fluorescent CFDA-SE dye and the plasma membrane was labeled with red fluorescent
labeled lipid analog, rhodamine DHPE. Figure 7 (b) is an image taken while keeping the
focus at the top membrane surface. The 9 μm diameter red ring corresponds to the top pore
edge where the red fluorescence from rhodamine DHPE intensifies on the pore edge within
the depth of focus of the microscope. Figure 7(c) is a reconstructed image based on an image
stack of 0.5 μm vertical step size, showing the vertical cross section of the cell trapped in a
pore. The cell part above the pore is more flat compared with SEM image. This might due to
the lipid analog labeling of cell membrane. Before filtration, the lipid labeled plasma
membrane seems to be more flexible and cells changed their shape with pseudopodia on
surface under conventional fluorescent microscope.
3.4 On-chip immunofluorescent staining of captured cells
Interrogation of specific protein expression of captured cell using IF is a common and
widely accepted technology for the CTC detection. It provides information on both cell
morphology and protein expression and location. In our model system, we have
demonstrated our ability to perform on-chip IF for the expression of CK. Figure 8(a) shows
a positive control with sample containing only tumor cells in PBS and Fig. 8(b) is the result
where culture cell lines were admixed in blood before filtration. In addition to single marker
analysis of captured cells, we demonstrated the capability for multi-marker IF analysis using
LNCaP cells, which express prostate specific antigen (PSA) in addition to CK.
Approximately 100 LNCaP cells were spiked in PBS, filtered through 3D microfilter
devices, and fixed with formalin. LNCaP cells were positive for both CK (Fig. 8(c)) and
PSA (Fig. 8(d)). Moreover, the cells were stained afterwards with nucleic acid selective
fluorescent dye, acridine orange (AO), as shown in (8E) to confirm the presence of cell
nucleus.
3.5 Viability studies of captured cells
To further validate the viability of the captured tumor cells on the 3D microfilter device, the
cells were cultured on device for 2 weeks and confirmed with a functional assay.
Immediately after filtering a sample of CFDA-SE labeled MCF-7 cells admixed in blood,
the 3D microfilter device was placed inside a petri dish containing complete culture media
and checked under the bright field microscopy (Fig. 9(a)) for device integrity and
fluorescence (Fig. 9(b)) for the presence of intact captured cells. Captured cells were
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cultured for 2 weeks inside the petri dish and most of the captured cells remained in the
same positions as shown in Fig. 9(c). It is interesting to note the number of green fluorescent
cells reduced from 71 to 61 in the same area during the 2 week period. It is possible these
cells were damaged during the filtration process, passively moved by the flow of fluids
when changing the media, or actively moved out of the pores and into the cell culture
container. Overall, after 2 weeks of cell culture, at least over 85% of the tumor cells had
intact cell membrane. A separate negative control was performed (data not shown), in which
CFDA-SE labeled MCF-7 cells were filtered through 3D microfilter device, checked for
bright green fluorescence. After treated with common fixative acetone, the original bright
green fluorescent spots turned dark. It is well known that acetone makes cell surface
permeable by removing lipids, precipitating proteins, and dehydrating the cells (Hoetelmans
et al. 2001). Thus CFDA-SE in cytoplasm leaks out of the cells leaving behind dark spots
that were originally occupied by bright green fluorescent cells.
Captured tumor cells on the 3D microdevice were tested with C12-resazurin functional assay
to demonstrate active metabolic activity. Colorless C12-resazurin (dodecyl-resazurin) readily
diffuses across cellular membrane and is reduced to red-fluorescent C12-resorufin in
metabolically active cells; therefore, marking metabolic active cells red. As shown in Fig.
8(e), metabolic active cells were labeled red along with a high background coming from
blood cells. Most of the captured tumor cells in Fig. 9(d) corresponds to a red fluorescent
area (arrows in Fig. 9(e)) indicating tumor cells were metabolically active even after 2
weeks of culture. Insets of Fig. 9(d) and (e) are positive controls with fresh MCF-7 cells
loaded on parylene surface and stained with C12-resorufin.
It is worth noting that parylene is an ideal building material for this filtration device because
of its unique properties. It is a mechanically strong (Young’s modulus 4 GPa and tensile
strength: 70 MPa) while malleable (elongation to break 200%) polymer. Being optically
transparent in visible range, this parylene device enables direct on-chip pathological
observation as demonstrated. Chemically, it is inert to most of the chemicals and solvents
used in standard chemical and biological laboratories yielding compatibility with most post-
processing (e.g. cell fixation, lysing, staining) steps to be performed on devices without
complexities and cell loss associated with added transfer step. Moreover, parylene is a
highly biocompatible polymer that can meet the highest standard for long-term implantation
or cell culture as shown. Lastly, parylene membrane filtration devices experiences less
clogging and membrane fouling due to reduced protein absorption and cell adhesion (Chang
et al. 2007).
4 Conclusion
Despite decades of effort, metastasis remains one of the major challenges of basic cancer
research. The main roadblock to characterizing CTCs and their involvement in cancer
progression has been the lack of a standard method for viable capture of rare occurring
CTCs in the complex fluid of blood. We have demonstrated here a 3D microfilter that can
enrich viable CTCs with ~86% capture efficiency in a few minutes. We confirmed intact cell
capture with SEM and confocal microscopy. Furthermore, the ability to perform on-chip
multimarker immunofluorescence analysis was demonstrated. The captured cells were
shown to be viable and metabolically active even after 2 weeks of cell culture on the device.
Further characterization and optimization of the device is underway and can potentially even
improve device performance. Future clinical testing with cancer patient blood samples can
provide more information on the performance of the device. The device is a valuable tool for
metastatic cancer diagnosis, treatment monitoring, personalized drug screening, and research
of CTCs.
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Fig. 1.
Device design. (a) Filtration process and forces on a trapped cell. FL: force caused by fluidic
pressure from top. FS: supporting force from bottom membrane. FT: tension stress force on
plasma membrane. (b) Design of a single hexagon-shaped microfilter patch
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Fig. 2.
Microfabrication process flow
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Fig. 3.
Fabricated 3D microfilter showing (a) the overall device, (b) one open window and (c) one
patch
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Fig. 4.
Device is assembled inside a housing cassette
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Fig. 5.
Finite element simulation. (a) Fluid field simulation of a single patch of a 3D microfilter
device without cells showing the velocity field. (b) Calculated tensions on the rim of an
empty pore and a plugged cell for 2D and 3D microfilter devices
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Fig. 6.
Comparison of 2D and 3D filters with unfixed CFDA-SE labeled MCF-7 cells. (a) cells
loaded on top surface of a 2D filter device. (b) cells filtered through a 2D filter device. (c)
cells filtered through a 3D filter device
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Fig. 7.
SEM and confocal imaging for captured tumor cells. (a) SEM image of a MCF-7 cell
captured on a 3D microfilter. (b) Confocal microscopy image focused on the top surface of
the 3D microfilter. (c) 3D reconstructed cross-sectional image
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Fig. 8.
Immunofluorescent staining of captured tumor cells. (a) MCF7 and LNCaP mix without
blood stained with anti-CK. (b) MCF7 and LNCaP mix with blood stained with anti-CK. (c)
double IF staining, LNCaP cells, without blood, red channel, anti-CK. (d) double IF
staining, LNCaP cells, without blood, green channel, anti-PSA. E: double IF staining,
LNCaP cells, without blood, green channel, AO
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Fig. 9.
Cell viability tests. (a) Device right after filtration under bright field illumination showing
the geometry of the patches and the two layers of pores. (b) Device right after filtration
under green fluorescent emission channel. (c) and (d) Device 14 days later under green
fluorescent emission channel. (e) Device 14 days later after C12-resazurin staining under red
fluorescent emission channel. White arrows in E point to positions of green fluorescent cells
in (d). (a), (b), and (c) were focused on the same area. (d) and (e) were focused on the same
area. Insets in (d) and (e) are positive controls where cells were loaded on flat parylene
surface
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Table 1
Capture efficiency measurement
Experiment number 1 2 3 4
Tumor cell count 288 317 281 299
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